User profiles for "author:Terrance G Johns"
Terrance G JohnsTelethon Kids Institute Verified email at telethonkids.org.au Cited by 10144 |
Targeting the ERBB family in cancer: couples therapy
N Tebbutt, MW Pedersen, TG Johns - Nature Reviews Cancer, 2013 - nature.com
The ERBB family of receptor tyrosine kinases has a central role in the tumorigenesis of many
types of solid tumour. Various therapeutics targeting these receptors have been approved …
types of solid tumour. Various therapeutics targeting these receptors have been approved …
The epidermal growth factor receptor variant III (EGFR v III): where wild things are altered
HK Gan, AN Cvrljevic, TG Johns - The FEBS journal, 2013 - Wiley Online Library
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human
epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene …
epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene …
The structure and function of myelin oligodendrocyte glycoprotein
TG Johns, CCA Bernard - Journal of neurochemistry, 1999 - Wiley Online Library
Myelin oligodendrocyte glycoprotein (MOG) is a quantitatively minor component of CNS
myelin whose function remains relatively unknown. As MOG is an autoantigen capable of …
myelin whose function remains relatively unknown. As MOG is an autoantigen capable of …
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
R Bonavia, A Mukasa, Y Narita, DWY Sah… - Genes & …, 2010 - genesdev.cshlp.org
Human solid tumors frequently have pronounced heterogeneity of both neoplastic and
normal cells on the histological, genetic, and gene expression levels. While current efforts …
normal cells on the histological, genetic, and gene expression levels. While current efforts …
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
AM Scott, FT Lee, N Tebbutt… - Proceedings of the …, 2007 - National Acad Sciences
An array of cell-surface antigens expressed by human cancers have been identified as
targets for antibody-based therapies. The great majority of these antibodies do not have …
targets for antibody-based therapies. The great majority of these antibodies do not have …
[HTML][HTML] Targeted drug delivery using genetically engineered diatom biosilica
B Delalat, VC Sheppard, S Rasi Ghaemi, S Rao… - Nature …, 2015 - nature.com
The ability to selectively kill cancerous cell populations while leaving healthy cells
unaffected is a key goal in anticancer therapeutics. The use of nanoporous silica-based …
unaffected is a key goal in anticancer therapeutics. The use of nanoporous silica-based …
Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2–7 or amplified epidermal growth factor receptor (EGFR) but not wild-type …
RB Luwor, TG Johns, C Murone, HJS Huang… - Cancer research, 2001 - AACR
The monoclonal antibody (mAb) 806 was raised against the delta2–7 epidermal growth
factor receptor (de2–7 EGFR or EGFRvIII), a truncated version of the EGFR commonly …
factor receptor (de2–7 EGFR or EGFRvIII), a truncated version of the EGFR commonly …
Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal …
A mutant epidermal growth factor receptor (variously called ΔEGFR, de2–7 EGFR, or
EGFRvIII) containing a deletion of 267 amino acids of the extracellular domain is frequently …
EGFRvIII) containing a deletion of 267 amino acids of the extracellular domain is frequently …
Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury
Modulating the behaviors of reactive astrocytes is a potential therapeutic strategy for
neurodegenerative diseases. We found that upregulation and activation of the epidermal …
neurodegenerative diseases. We found that upregulation and activation of the epidermal …
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients
KV Lu, S Zhu, A Cvrljevic, TT Huang, S Sarkaria… - Cancer research, 2009 - AACR
Activating epidermal growth factor receptor (EGFR) mutations are common in many cancers
including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and …
including glioblastoma. However, clinical responses to EGFR inhibitors are infrequent and …